Leukemia Lymphocytic Chronic B-cell
📧 Sign up to get email alerts when something new happens for Leukemia Lymphocytic Chronic B-cell.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-10EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG
EMA confirms authorisation of Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias; product is authorised fo…
-
EMA approval · 2026-07-06EMA Authorised: Calquence (acalabrutinib;acalabrutinib maleate) — AstraZeneca AB
AstraZeneca's Calquence (acalabrutinib, acalabrutinib maleate) has been authorised by EMA for chronic lymphocytic leukemia and related B-cel…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial update for ASN002 in relapsed/refractory lymphoma and advanced solid tumors; the study status is TERMINATED with re…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial update evaluating a CD19-targeted CAR-T therapy for relapsed/refractory CD19-positive B cell leukemia and lymphom…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update for a CD19-targeted CAR-T cell therapy in relapsed/refractory CD19+ B-cell leukemias and lymphomas.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL [Phase 1, Phase 2]
Phase 1/2 trial of MT-3724 in relapsed or refractory diffuse large B-cell lymphoma and related B-cell hematologic malignancies; the study is…
-
EMA withdrawal · 2020-06-24EMA Application withdrawn: Rituximab Mabion (rituximab) — Mabion Spolka Akcyjna
The EMA application for Rituximab Mabion (rituximab) by Mabion Spolka Akcyjna has been withdrawn.
-
EMA withdrawal · 2012-08-15EMA Withdrawn: MabCampath (alemtuzumab) — Genzyme Europe B.V.
EMA withdrew MabCampath (alemtuzumab) from the market.